# ASGR1 may link smoking to heart disease > Genetic analyses place ASGR1 on one possible route from smoking to ischemic heart disease, but pleiotropy and population limits prevent calling it the culprit or a treatment target. _Source: Peer-reviewed Nature Cardiovascular Research study, verified against PubMed PMID 42773283 and Crossref metadata · 2026-10-12 · 7 min read · Verified against primary sources_ Canonical: https://iyu.app/e/asgr1-smoking-ischemic-heart-disease ## The 60-second version Genetic analyses identify ASGR1 as one possible mediator between smoking exposure and ischemic heart disease, while leaving causality and clinical value unresolved. **Key points** - The study screened 2,922 plasma proteins and found 93 associated with genetically predicted smoking exposure. - ASGR1 levels and ischemic heart disease showed a reported colocalization posterior probability of 0.91. - Two-step Mendelian randomization estimated 6.35% mediation, with a 95% confidence interval of 2.61% to 10.09%. - Never-smoker sensitivity analysis raised possible horizontal pleiotropy, with BMI as a potential alternate pathway. - European-ancestry data and the absence of intervention evidence limit immediate clinical use. **Verdict.** ASGR1 is a credible mechanism to investigate, but the evidence does not justify calling it smoking's culprit protein, a personal risk test or a treatment target. ## Full explainer A proteome-wide genetic study identifies asialoglycoprotein receptor 1, or ASGR1, as a potential molecular link between smoking and ischemic heart disease. The analysis supports ASGR1 as a research lead, not as the single protein that makes smoking damage the heart and not yet as a validated biomarker or drug target. > **⚑ Caveat:** The 6.35% mediation estimate and other headline results come from the study's genetic models. Mendelian randomization can strengthen causal inference, but it depends on assumptions and cannot by itself establish that changing ASGR1 will prevent heart attacks. ### What was tested — The study searched across the plasma proteome The researchers combined genetic instruments for smoking-related exposures with genetic data on 2,922 plasma proteins in populations of European ancestry. Ninety-three proteins showed significant associations with genetically predicted smoking exposure. ASGR1 stood out because the smoking instruments pointed toward higher circulating levels and the same genomic region also supported an association with ischemic heart disease. - **2,922** — proteins included in the proteome-wide analysis - **93** — proteins significantly associated with genetically predicted smoking exposure - **0.91** — posterior probability for the reported ASGR1-IHD colocalization hypothesis Colocalization asks whether two associations in a region are likely to share the same underlying genetic signal. The reported posterior probability of 0.91 supports a shared signal for ASGR1 levels and ischemic heart disease. It does not show, on its own, that the protein is the biological mechanism connecting them. ### How to read the estimate — Six percent is a modeled share, not a clinical prediction In a two-step Mendelian randomization analysis, the authors estimated that ASGR1 mediated 6.35% of smoking's effect on ischemic heart disease, with a 95% confidence interval from 2.61% to 10.09%. In plain language, the model assigns a modest portion of the smoking-IHD relationship to a pathway involving ASGR1. Most of the relationship remains outside that pathway. - **Finding:** Genetically predicted smoking exposure was associated with higher ASGR1 levels, and ASGR1-related genetic signals were associated with IHD. - **Mediation estimate:** 6.35% of the modeled smoking effect on IHD, with a 95% confidence interval of 2.61% to 10.09%. - **What it is not:** It is not a statement that ASGR1 causes 6.35% of heart attacks or predicts an individual's risk with that accuracy. - **Clinical status:** No screening threshold, treatment strategy or patient benefit was established. > ASGR1 is a plausible waypoint in a much larger causal network, not a verdict on one person's heart risk. ### Why uncertainty remains — One genetic variant can influence several pathways Mendelian randomization uses inherited variants as proxies for exposures. Its interpretation is strongest when a variant affects the outcome only through the pathway being tested. Horizontal pleiotropy violates that condition: the same variant may influence heart disease through another biological route rather than through smoking and ASGR1 in sequence. The authors therefore examined people who had never smoked. The residual ASGR1-IHD association was not statistically significant, but its pattern was consistent with possible horizontal pleiotropy. Body mass index was implicated as one potential contributing pathway. This sensitivity result does not erase the main association, but it makes the simple chain from smoking to ASGR1 to heart disease less certain. Network analysis added another warning against a single-protein story. Genetically predicted ASGR1 levels were inversely associated with more than 100 other plasma proteins, including growth arrest-specific 6. The ASGR1 cis-pQTL rs55714927 also acted as a trans-pQTL for those proteins, suggesting broad downstream or parallel effects that need experimental separation. ### What the study cannot answer — Genetic evidence is not a smoking intervention - **1.** The analysis used genetically predicted exposures and protein levels; it did not randomize people to smoke or measure the effect of quitting on ASGR1. - **2.** The main analyses were conducted in European-ancestry populations, so transfer to other ancestries requires direct evaluation. - **3.** Circulating protein associations do not prove which tissue, cell type or molecular action drives disease. - **4.** A potential biomarker must still show reproducible measurement, added predictive value and clinical usefulness beyond established risk factors. - **5.** A treatment target requires intervention evidence that altering the protein improves outcomes without unacceptable harm. ### What comes next — Test the pathway before testing patients The useful next steps are replication in more ancestries, laboratory experiments that separate ASGR1 from BMI and other pleiotropic routes, and prospective studies asking whether ASGR1 adds information beyond smoking history and standard cardiovascular risk markers. For readers, the practical conclusion does not change: this result refines research into how smoking harms the cardiovascular system; it does not replace smoking cessation or established prevention. ## Primary sources - [Telegram post 1537](https://t.me/CNSmydream/1537) - [Nature Cardiovascular Research paper](https://doi.org/10.1038/s44161-026-00871-x) - [PubMed record (PMID 42773283)](https://pubmed.ncbi.nlm.nih.gov/42773283/) - [Crossref metadata](https://api.crossref.org/works/10.1038/s44161-026-00871-x) - [World Heart Federation policy brief (PMID 38973985)](https://doi.org/10.5334/gh.1334) --- _Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._